{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:13:24Z","timestamp":1793146404882,"version":"4.5.0"},"reference-count":55,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,4]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>NPM1 is a multifunctional phosphoprotein with key roles in ribosome biogenesis among its many functions. NPM1 gene mutations drive 30% of acute myeloid leukemia (AML) cases. The mutations disrupt a nucleolar localization signal and create a novel nuclear export signal, leading to cytoplasmic displacement of the protein (NPM1c). NPM1c mutations prime hematopoietic progenitors to leukemic transformation, but their precise molecular consequences remain elusive. Here, we first evaluate the effects of isolated NPM1c mutations on the global proteome of preleukemic hematopoietic stem and progenitor cells (HSPCs) using conditional knockin Npm1cA\/+ mice. We discover that many proteins involved in ribosome biogenesis are significantly depleted in these murine HSPCs, but also importantly in human NPM1-mutant AMLs. In line with this, we found that preleukemic Npm1cA\/+ HSPCs display higher sensitivity to RNA polymerase I inhibitors, including actinomycin D (ActD), compared with Npm1+\/+ cells. Combination treatment with ActD and venetoclax inhibited the growth and colony-forming ability of preleukemic and leukemic NPM1c+ cells, whereas low-dose ActD treatment was able to resensitize resistant NPM1c+ cells to venetoclax. Furthermore, using data from CRISPR dropout screens, we identified and validated TSR3, a 40S ribosomal maturation factor whose knockout preferentially inhibited the proliferation of NPM1c+ AML cells by activating a p53-dependent apoptotic response. Similarly, to low-dose ActD treatment, TSR3 depletion could partially restore sensitivity to venetoclax in therapy-resistant NPM1c+ AML models. Our findings propose that targeted disruption of ribosome biogenesis should be explored as a therapeutic strategy against NPM1-mutant AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024026113","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T15:20:59Z","timestamp":1750864859000},"page":"1239-1252","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in\n                    <i>NPM1<\/i>\n                    -mutant AML"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1925-3441","authenticated-orcid":false,"given":"Aristi","family":"Damaskou","sequence":"first","affiliation":[{"name":"1Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"},{"name":"2Department of Haematology, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5129-7295","authenticated-orcid":false,"given":"Rachael","family":"Wilson","sequence":"additional","affiliation":[{"name":"1Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"},{"name":"2Department of Haematology, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3134-1276","authenticated-orcid":false,"given":"Malgorzata","family":"Gozdecka","sequence":"additional","affiliation":[{"name":"1Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"},{"name":"2Department of Haematology, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1390-6592","authenticated-orcid":false,"given":"George","family":"Giotopoulos","sequence":"additional","affiliation":[{"name":"1Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"},{"name":"2Department of Haematology, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5077-3798","authenticated-orcid":false,"given":"Ryan","family":"Asby","sequence":"additional","affiliation":[{"name":"1Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"},{"name":"2Department of Haematology, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1842-5838","authenticated-orcid":false,"given":"Maria","family":"Eleftheriou","sequence":"additional","affiliation":[{"name":"1Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"},{"name":"2Department of Haematology, University of Cambridge, Cambridge, United Kingdom"},{"name":"3Milner Therapeutics Institute, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muxin","family":"Gu","sequence":"additional","affiliation":[{"name":"1Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"},{"name":"2Department of Haematology, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-4525","authenticated-orcid":false,"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[{"name":"4Centre de Recherches en Canc\u00e9rologie de Toulouse, Universit\u00e9 de Toulouse, INSERM U1037, Centre National de la Recherche Scientifique U5077, Toulouse, France"},{"name":"5LabEx Toucan, Toulouse, France"},{"name":"6\u00c9quipe Labellis\u00e9e Ligue Nationale Contre le Cancer 2023, Toulouse, France"},{"name":"7Service d'H\u00e9matologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1878-9129","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Mansat-De Mas","sequence":"additional","affiliation":[{"name":"4Centre de Recherches en Canc\u00e9rologie de Toulouse, Universit\u00e9 de Toulouse, INSERM U1037, Centre National de la Recherche Scientifique U5077, Toulouse, France"},{"name":"5LabEx Toucan, Toulouse, France"},{"name":"6\u00c9quipe Labellis\u00e9e Ligue Nationale Contre le Cancer 2023, Toulouse, France"},{"name":"7Service d'H\u00e9matologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0063-4404","authenticated-orcid":false,"given":"Francois","family":"Vergez","sequence":"additional","affiliation":[{"name":"4Centre de Recherches en Canc\u00e9rologie de Toulouse, Universit\u00e9 de Toulouse, INSERM U1037, Centre National de la Recherche Scientifique U5077, Toulouse, France"},{"name":"5LabEx Toucan, Toulouse, France"},{"name":"6\u00c9quipe Labellis\u00e9e Ligue Nationale Contre le Cancer 2023, Toulouse, France"},{"name":"7Service d'H\u00e9matologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4755-2884","authenticated-orcid":false,"given":"Ambrine","family":"Sahal","sequence":"additional","affiliation":[{"name":"4Centre de Recherches en Canc\u00e9rologie de Toulouse, Universit\u00e9 de Toulouse, INSERM U1037, Centre National de la Recherche Scientifique U5077, Toulouse, France"},{"name":"5LabEx Toucan, Toulouse, France"},{"name":"6\u00c9quipe Labellis\u00e9e Ligue Nationale Contre le Cancer 2023, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1956-2778","authenticated-orcid":false,"given":"Binje","family":"Vick","sequence":"additional","affiliation":[{"name":"8Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum M\u00fcnchen, German Research Center for Environmental Health, Munich, Germany"},{"name":"9German Cancer Consortium, Partner Site Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia K.","family":"Papachristou","sequence":"additional","affiliation":[{"name":"10Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-5059","authenticated-orcid":false,"given":"Ashley","family":"Sawle","sequence":"additional","affiliation":[{"name":"10Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2913-0012","authenticated-orcid":false,"given":"Eliza","family":"Yankova","sequence":"additional","affiliation":[{"name":"1Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"},{"name":"2Department of Haematology, University of Cambridge, Cambridge, United Kingdom"},{"name":"3Milner Therapeutics Institute, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Dudek","sequence":"additional","affiliation":[{"name":"1Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"},{"name":"2Department of Haematology, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Liu","sequence":"additional","affiliation":[{"name":"1Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"},{"name":"2Department of Haematology, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9431-8428","authenticated-orcid":false,"given":"James","family":"Russell","sequence":"additional","affiliation":[{"name":"1Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"},{"name":"2Department of Haematology, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Rak","sequence":"additional","affiliation":[{"name":"1Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"},{"name":"2Department of Haematology, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9596-7833","authenticated-orcid":false,"given":"Christine","family":"Hilcenko","sequence":"additional","affiliation":[{"name":"1Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"},{"name":"2Department of Haematology, University of Cambridge, Cambridge, United Kingdom"},{"name":"11Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom"},{"name":"12Department of Infectious Disease, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"D\u2019Santos","sequence":"additional","affiliation":[{"name":"10Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irmela","family":"Jeremias","sequence":"additional","affiliation":[{"name":"8Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum M\u00fcnchen, German Research Center for Environmental Health, Munich, Germany"},{"name":"9German Cancer Consortium, Partner Site Munich, Munich, Germany"},{"name":"13Department of Pediatrics, Dr. von Hauner Children\u2019s Hospital, University Hospital, Ludwig Maximilian University, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-2032","authenticated-orcid":false,"given":"Jean-Emmanuel","family":"Sarry","sequence":"additional","affiliation":[{"name":"4Centre de Recherches en Canc\u00e9rologie de Toulouse, Universit\u00e9 de Toulouse, INSERM U1037, Centre National de la Recherche Scientifique U5077, Toulouse, France"},{"name":"5LabEx Toucan, Toulouse, France"},{"name":"6\u00c9quipe Labellis\u00e9e Ligue Nationale Contre le Cancer 2023, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4865-7648","authenticated-orcid":false,"given":"Konstantinos","family":"Tzelepis","sequence":"additional","affiliation":[{"name":"1Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"},{"name":"2Department of Haematology, University of Cambridge, Cambridge, United Kingdom"},{"name":"3Milner Therapeutics Institute, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0312-161X","authenticated-orcid":false,"given":"Brian J. P.","family":"Huntly","sequence":"additional","affiliation":[{"name":"1Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"},{"name":"2Department of Haematology, University of Cambridge, Cambridge, United Kingdom"},{"name":"11Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9277-4553","authenticated-orcid":false,"given":"Alan J.","family":"Warren","sequence":"additional","affiliation":[{"name":"1Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"},{"name":"2Department of Haematology, University of Cambridge, Cambridge, United Kingdom"},{"name":"11Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Tavana","sequence":"additional","affiliation":[{"name":"14Hematology R&D, AstraZeneca, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4337-8022","authenticated-orcid":false,"given":"George S.","family":"Vassiliou","sequence":"additional","affiliation":[{"name":"1Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom"},{"name":"2Department of Haematology, University of Cambridge, Cambridge, United Kingdom"},{"name":"15Department of Haematology, Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2025090411222074700_bib1","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1128\/MCB.26.10.3798-3809.2006","article-title":"Nucleophosmin is essential for ribosomal protein L5 nuclear export","volume":"26","author":"Yu","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"7","key":"2025090411222074700_bib2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/ncb814","article-title":"Nucleophosmin regulates the stability and transcriptional activity of p53","volume":"4","author":"Colombo","year":"2002","journal-title":"Nat Cell Biol"},{"issue":"5","key":"2025090411222074700_bib3","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1097-2765(03)00431-3","article-title":"Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation","volume":"12","author":"Itahana","year":"2003","journal-title":"Mol Cell"},{"issue":"17","key":"2025090411222074700_bib4","doi-asserted-by":"crossref","first-page":"7534","DOI":"10.1128\/MCB.25.17.7534-7545.2005","article-title":"Human histone chaperone Nucleophosmin enhances acetylation-dependent chromatin transcription","volume":"25","author":"Swaminathan","year":"2005","journal-title":"Mol Cell Biol"},{"issue":"Pt 1","key":"2025090411222074700_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1042\/BJ20042033","article-title":"A proteomics approach for the identification of nucleophosmin and heterogeneous nuclear ribonucleoprotein C1\/C2 as chromatin-binding proteins in response to DNA double-strand breaks","volume":"388","author":"Lee","year":"2005","journal-title":"Biochem J"},{"issue":"40","key":"2025090411222074700_bib6","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1038\/sj.onc.1205708","article-title":"The role of nucleophosmin in centrosome duplication","volume":"21","author":"Okuda","year":"2002","journal-title":"Oncogene"},{"issue":"7","key":"2025090411222074700_bib7","doi-asserted-by":"crossref","first-page":"e112699","DOI":"10.15252\/embj.2022112699","article-title":"Ribosome biogenesis factors\u2014from names to functions","volume":"42","author":"D\u00f6rner","year":"2023","journal-title":"EMBO J"},{"issue":"7","key":"2025090411222074700_bib8","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.cell.2016.04.047","article-title":"Coexisting liquid phases underlie nucleolar sub-compartments","volume":"165","author":"Feric","year":"2016","journal-title":"Cell"},{"key":"2025090411222074700_bib9","doi-asserted-by":"crossref","first-page":"e13571","DOI":"10.7554\/eLife.13571","article-title":"Nucleophosmin integrates within the nucleolus via multi-modal interactions with proteins displaying R-rich linear motifs and rRNA","volume":"5","author":"Mitrea","year":"2016","journal-title":"Elife"},{"issue":"1","key":"2025090411222074700_bib10","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41467-018-03255-3","article-title":"Self-interaction of NPM1 modulates multiple mechanisms of liquid-liquid phase separation","volume":"9","author":"Mitrea","year":"2018","journal-title":"Nat Commun"},{"issue":"10","key":"2025090411222074700_bib11","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/s41588-019-0502-z","article-title":"Germline NPM1 mutations lead to altered rRNA 2\u2032-O-methylation and cause dyskeratosis congenita","volume":"51","author":"Nachmani","year":"2019","journal-title":"Nat Genet"},{"issue":"3","key":"2025090411222074700_bib12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med"},{"issue":"23","key":"2025090411222074700_bib13","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"2025090411222074700_bib14","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/leu.2009.124","article-title":"Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications","volume":"23","author":"Falini","year":"2009","journal-title":"Leukemia"},{"issue":"5","key":"2025090411222074700_bib15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood.2019002697","article-title":"Impact of NPM1\/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia","volume":"135","author":"D\u00f6hner","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2025090411222074700_bib16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2025090411222074700_bib17","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","article-title":"Advances in the treatment of acute myeloid leukemia: New drugs and new challenges","volume":"10","author":"Short","year":"2020","journal-title":"Cancer Discov"},{"issue":"10","key":"2025090411222074700_bib18","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/s41375-022-01666-2","article-title":"Current status and future perspectives in targeted therapy of NPM1-mutated AML","volume":"36","author":"Ranieri","year":"2022","journal-title":"Leukemia"},{"issue":"10","key":"2025090411222074700_bib19","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s41588-021-00925-9","article-title":"Mutational synergy during leukemia induction remodels chromatin accessibility, modification and 3-Dimensional DNA topology to alter gene expression","volume":"53","author":"Yun","year":"2021","journal-title":"Nat Genet"},{"issue":"5","key":"2025090411222074700_bib20","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/ng.796","article-title":"Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice","volume":"43","author":"Vassiliou","year":"2011","journal-title":"Nat Genet"},{"issue":"17","key":"2025090411222074700_bib21","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1182\/blood-2017-01-760595","article-title":"Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia","volume":"130","author":"Dovey","year":"2017","journal-title":"Blood"},{"issue":"13","key":"2025090411222074700_bib22","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/blood.2022016033","article-title":"Proteomic and phosphoproteomic landscapes of acute myeloid leukemia","volume":"140","author":"Kramer","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2025090411222074700_bib23","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.celrep.2016.09.079","article-title":"A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia","volume":"17","author":"Tzelepis","year":"2016","journal-title":"Cell Rep"},{"issue":"12","key":"2025090411222074700_bib24","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/ng.3984","article-title":"Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells","volume":"49","author":"Meyers","year":"2017","journal-title":"Nat Genet"},{"key":"2025090411222074700_bib25","doi-asserted-by":"publisher","DOI":"10.1101\/720243","article-title":"Extracting biological insights from the project achilles genome-scale CRISPR screens in cancer cell lines","author":"Dempster","year":"31  2019","journal-title":"bioRxiv"},{"issue":"21","key":"2025090411222074700_bib26","doi-asserted-by":"crossref","first-page":"7971","DOI":"10.1128\/MCB.20.21.7971-7979.2000","article-title":"Yeast Krr1p physically and functionally interacts with a novel essential Kri1p, and both proteins are required for 40S ribosome biogenesis in the nucleolus","volume":"20","author":"Sasaki","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"12","key":"2025090411222074700_bib27","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/nchembio.1093","article-title":"Oxygenase-catalyzed ribosome hydroxylation occurs in prokaryotes and humans","volume":"8","author":"Ge","year":"2012","journal-title":"Nat Chem Biol"},{"issue":"7605","key":"2025090411222074700_bib28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nature17942","article-title":"Diverse roles of assembly factors revealed by structures of late nuclear pre-60S ribosomes","volume":"534","author":"Wu","year":"2016","journal-title":"Nature"},{"key":"2025090411222074700_bib29","doi-asserted-by":"crossref","first-page":"620925","DOI":"10.3389\/fcell.2021.620925","article-title":"Advances in the relationship between regulator of ribosome synthesis 1 (RRS1) and diseases","volume":"9","author":"Hua","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"2025090411222074700_bib30","doi-asserted-by":"crossref","first-page":"e1003708","DOI":"10.1371\/journal.pgen.1003708","article-title":"The ribosomal protein Rpl22 controls ribosome composition by directly repressing expression of its own paralog, Rpl22l1","volume":"9","author":"O\u2019Leary","year":"2013","journal-title":"PLoS Genet"},{"issue":"6","key":"2025090411222074700_bib31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.blre.2011.06.001","article-title":"Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?","volume":"25","author":"Falini","year":"2011","journal-title":"Blood Rev"},{"issue":"12","key":"2025090411222074700_bib32","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1056\/NEJMc1509584","article-title":"Dactinomycin in NPM1 -mutated acute myeloid leukemia","volume":"373","author":"Falini","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"2025090411222074700_bib33","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1038\/s41375-021-01192-7","article-title":"Dactinomycin induces complete remission associated with nucleolar stress response in relapsed\/refractory NPM1-mutated AML","volume":"35","author":"Gionfriddo","year":"2021","journal-title":"Leukemia"},{"issue":"16","key":"2025090411222074700_bib34","doi-asserted-by":"crossref","first-page":"12416","DOI":"10.1074\/jbc.M109.074211","article-title":"Chemotherapeutic drugs inhibit ribosome biogenesis at various levels","volume":"285","author":"Burger","year":"2010","journal-title":"J Biol Chem"},{"key":"2025090411222074700_bib35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.semcdb.2022.04.001","article-title":"Nucleolar stress: from development to cancer","volume":"136","author":"Lafita-Navarro","year":"2023","journal-title":"Semin Cell Dev Biol"},{"key":"2025090411222074700_bib36","doi-asserted-by":"crossref","first-page":"RP88799","DOI":"10.7554\/eLife.88799","article-title":"Distinct states of nucleolar stress induced by anticancer drugs","volume":"12","author":"Potapova","year":"2023","journal-title":"Elife"},{"issue":"2","key":"2025090411222074700_bib37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ijc.2910520227","article-title":"Schedule-dependent effects of two consecutive, divided, low doses of actinomycin D on translocation of protein B23, inhibition of cell growth and RNA synthesis in hela cells","volume":"52","author":"Yung","year":"1992","journal-title":"Int J Cancer"},{"issue":"2","key":"2025090411222074700_bib38","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3390\/cells9020266","article-title":"Targeting the RNA polymerase I transcription for cancer therapy comes of age","volume":"9","author":"Ferreira","year":"2020","journal-title":"Cells"},{"issue":"1","key":"2025090411222074700_bib39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2013.12.009","article-title":"A targeting modality for destruction of RNA polymerase I that possesses anticancer activity","volume":"25","author":"Peltonen","year":"2014","journal-title":"Cancer Cell"},{"issue":"4","key":"2025090411222074700_bib40","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/0008-5472.CAN-10-1728","article-title":"Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth","volume":"71","author":"Drygin","year":"2011","journal-title":"Cancer Res"},{"issue":"1","key":"2025090411222074700_bib41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"Dinardo","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2025090411222074700_bib42","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","article-title":"Outcomes of older patients with NPM1-mutated AML: Current treatments and the promise of venetoclax-based regimens","volume":"4","author":"Lachowiez","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"2025090411222074700_bib43","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/s41375-023-01951-8","article-title":"The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax\/azacitidine in acute myeloid leukemia","volume":"37","author":"Weidenauer","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2025090411222074700_bib44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1042\/BJ20061088","article-title":"BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo","volume":"401","author":"Sapkota","year":"2007","journal-title":"Biochem J"},{"issue":"5","key":"2025090411222074700_bib45","doi-asserted-by":"crossref","first-page":"107611","DOI":"10.1016\/j.celrep.2020.107611","article-title":"Loss of m 1 acp 3 J Ribosomal RNA Modification Is a Major Feature of Cancer","volume":"31","author":"Babaian","year":"2020","journal-title":"Cell Rep"},{"issue":"9","key":"2025090411222074700_bib46","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1093\/nar\/gkw244","article-title":"Ribosome biogenesis factor Tsr3 is the aminocarboxypropyl transferase responsible for 18S rRNA hypermodification in yeast and humans","volume":"44","author":"Meyer","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"2025090411222074700_bib47","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/2159-8290.CD-22-0366","article-title":"Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia","volume":"13","author":"Uckelmann","year":"2023","journal-title":"Cancer Discov"},{"issue":"3","key":"2025090411222074700_bib48","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1158\/2159-8290.CD-22-0424","article-title":"Mutant NPM1 hijacks transcriptional hubs to maintain pathogenic gene programs in acute myeloid leukemia","volume":"13","author":"Wang","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"2025090411222074700_bib49","doi-asserted-by":"crossref","first-page":"23780","DOI":"10.1038\/s41598-024-75168-9","article-title":"Integrating holotomography and deep learning for rapid detection of NPM1 mutations in AML","volume":"14","author":"Kim","year":"2024","journal-title":"Sci Rep"},{"issue":"12","key":"2025090411222074700_bib50","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1158\/2159-8290.CD-21-0177","article-title":"Actinomycin D targets NPM1c-primed mitochondria to restore PML-driven senescence in AML therapy","volume":"11","author":"Wu","year":"2021","journal-title":"Cancer Discov"},{"issue":"6","key":"2025090411222074700_bib51","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1535-6108(03)00134-X","article-title":"Regulation of HDM2 activity by the ribosomal protein L11","volume":"3","author":"Lohrum","year":"2003","journal-title":"Cancer Cell"},{"issue":"44","key":"2025090411222074700_bib52","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1038\/onc.2008.189","article-title":"Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway","volume":"27","author":"Horn","year":"2008","journal-title":"Oncogene"},{"issue":"14","key":"2025090411222074700_bib53","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1101\/gad.261792.115","article-title":"Structure of human MDM2 complexed with RPL11 reveals the molecular basis of p53 activation","volume":"29","author":"Zheng","year":"2015","journal-title":"Genes Dev"},{"issue":"7","key":"2025090411222074700_bib54","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"issue":"6","key":"2025090411222074700_bib55","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ccell.2017.11.003","article-title":"Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: mechanisms and superior antileukemic efficacy","volume":"32","author":"Pan","year":"2017","journal-title":"Cancer Cell"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/10\/1239\/2411097\/blood_bld-2024-026113-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/10\/1239\/2411097\/blood_bld-2024-026113-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T15:25:27Z","timestamp":1756999527000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/10\/1239\/537926\/Posttranscriptional-depletion-of-ribosome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026113","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,4]]},"published":{"date-parts":[[2025,9,4]]}}}